Research collaboration will focus on modified adenovirus development

Calgary, AB August 1, 2003 Oncolytics Biotech says it has entered into a research collaboration with Dr Ramon Alemany of the Institut Catala d’Oncologia, Barcelona, Spain to develop modified adenoviruses that are selective for Ras mediated cancers.

“As approximately two-thirds of human cancers have some form of mutation that leads to Ras activation, adding a new generation of viruses that are designed to be selective for RAS mediated tumours will expand our oncology focus,” says Dr Matt Coffey, vice president, product development of Oncolytics. “Dr Alemany has been influential in the development of additional viral constructs for clinical development and we look forward to the benefit of his experience in this collaboration.”